Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma: early-phase trial registry
2 of 2 indexed Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #7,188 of 28,707 conditions by registered trial count.
2 US clinical trials · 2 currently recruiting · #7,188 of 28,707 conditions by registered trial count
Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma: 2 US clinical trials tracked, 2 recruiting.
Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma is the subject of 2 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Joseph Tuscano, running 1 of these trials.
Enrollment posture brief
Registry condition refractory-transformed-follicular-lymphoma-to-diffuse-large-b-cell-lymphoma
OPEN 2 | RECR 100% | LATE 0 | EARLY 2 | RANK #7188 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)
Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma lists 2 open slots (100% of 2 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma is recruiting above its size-band peers.
2 of 2 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
2 total, page 1 of 1
Fecal Microbiome Transplant to Remodel Intestinal Microbiota for Patients With Relapsed or Refractory Lymphoma With Exposure to High-Risk Antibiotics Who Are Receiving Chimeric Antigen Receptor T Cells
City of Hope Medical Center
NCT07042438
Odronextamab for the Treatment of Relapsed and Refractory Diffuse Large B-cell Lymphoma Before and After Chimeric Antigen Receptor T-cell Therapy
Joseph Tuscano
NCT06854159
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma page
2 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 2 Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Joseph Tuscano sponsors the most Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma trials on record, review their full trial history before evaluating a specific study. See Joseph Tuscano's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma condition card totals 2 registered trials; most-linked intervention Axicabtagene Ciloleucel; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.